cannabidiol

Overview

Cannabidiol (CBD) is a non-intoxicating cannabinoid derived from Cannabis sativa that has attracted substantial biomedical interest because of its broad pharmacological profile. In the recent literature provided, CBD is discussed as a candidate with anti-inflammatory, neuroprotective, anticonvulsant, and anticancer activity, with particular relevance to refractory epilepsy, ischemic stroke, hyperglycemia-associated phenotypes, and breast cancer. It is also being evaluated in drug-repositioning frameworks as a host-targeted compound across interconnected disease networks.

Mechanistically, the studies summarized here portray cannabidiol as a pleiotropic bioactive molecule rather than a single-target agent. Its reported effects include modulation of inflammatory pathways, potential lowering of blood glucose, seizure suppression, and neuroprotection. At the same time, the literature emphasizes practical limitations such as low potency, the need for high dosing, and safety concerns including drowsiness, gastric adverse effects, and potential hepatotoxicity. These features have motivated formulation research, analog development, and delivery strategies such as exosomes and nanoparticles.

Focus of Latest Publications

Recent publications on cannabidiol have focused heavily on improving its delivery, bioavailability, and therapeutic performance through formulation strategies and combination approaches. Several studies examined cannabidiol in lipid-based, amorphous, or vesicular systems, including nanostructured lipid carriers with piperine, hot-melt-extruded PVP K30-phosphatidylcholine dispersions, exosome-based oral delivery, and multifunctional nanoparticles. Across these reports, cannabidiol was paired with carriers or co-ingredients to address its poor oral solubility and absorption. The piperine co-delivery study found that cannabidiol bioaccessibility depended strongly on the cannabidiol source, and that piperine codelivery with cannabidiol isolate doubled systemic exposure in mice. Similarly, amorphous polymer-phospholipid dispersions substantially increased cannabidiol solubility, dissolution, and in vitro permeability, while exosomal and folic acid-functionalized exosomal formulations improved tumor targeting and oral anticancer performance in breast cancer models.

Other recent work explored cannabidiol in disease-directed preclinical models, especially those involving inflammation, pain, neuroprotection, and tissue repair. In osteoarthritis, a microfluidics-enabled nanoparticle preloaded with cannabidiol improved lubrication, reduced inflammatory cytokines, preserved cartilage matrix, and mitigated joint damage in vitro and in vivo, with transcriptomic evidence implicating downregulation of SCN9A and inhibition of Nav1.7-related pathways. In ischemic stroke, a macrophage membrane-coated nanoparticle carrying cannabidiol, polysaccharide, and apigenin reduced brain injury, neuroinflammation, and neuronal apoptosis in a rat middle cerebral artery occlusion model, with effects linked to inhibition of NLRP3/NF-κB signaling. In rheumatoid arthritis, cannabidiol was studied in combination with methotrexate, with the abstract reporting investigation of synergistic efficacy, safety, and mechanism through STAT3/NF-κB signaling and M1 macrophage polarization.

Several studies also evaluated cannabidiol in neurological, metabolic, and perioperative settings. In zebrafish seizure models, synthetic cannabidiol analogs were screened for antiseizure activity, with some analogs outperforming cannabidiol in suppressing pentylenetetrazole-induced seizures and reducing neural hyperactivity. In hyperglycemic zebrafish, cannabidiol co-exposure improved optomotor performance but did not significantly lower blood glucose, and it did not restore all retinal electrophysiological deficits, suggesting only partial mitigation of hyperglycemic sequelae. A neuropathic pain study examined a cannabidiol-enriched Cannabis sp. extract administered via the oral mucosa for two weeks and reported moderate reduction in cold hyperalgesia in rats. In veterinary anesthesia, perioperative full-spectrum cannabis oil containing cannabidiol and tetrahydrocannabinol reduced propofol and sevoflurane requirements and increased sedation scores in female dogs undergoing mastectomy and ovariohysterectomy, without observed clinical complications.

Clinical pharmacokinetic work has also continued to compare cannabidiol formulations in humans. A randomized crossover phase I study evaluated an encapsulated powdered emulsion formulation versus an oil-based formulation under fasted and fed conditions in healthy participants, focusing on pharmacokinetics, tolerability, and safety. Together, these recent publications portray cannabidiol as a compound being actively optimized for delivery and explored across diverse preclinical and translational contexts, with recurring themes of enhanced bioavailability, multimodal anti-inflammatory or neuroprotective activity, and formulation-dependent effects on efficacy.